Evidence map›Paper›PMID 33078479›Full record

ArticlePharmacotherapy2020

Prescription Medication Use in Older Adults Without Major Cardiovascular Disease Enrolled in the Aspirin in Reducing Events in the Elderly (ASPREE) Clinical Trial.

Jessica E Lockery, Michael E Ernst, Jonathan C Broder, Suzanne G Orchard, Anne Murray, Mark R Nelson, Nigel P Stocks, Rory Wolfe, Christopher M Reid, Danny Liew and 2 more

Open access · greenAbstract read
In one paragraph

Article in Pharmacotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Jessica E LockeryDepartment of Epidemiology & Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0001-6664-1239
Michael E ErnstDepartment of Pharmacy Practice and Science, College of Pharmacy and Department of Family Medicine, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.
Jonathan C BroderDepartment of Epidemiology & Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Suzanne G OrchardDepartment of Epidemiology & Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Anne MurrayHennepin Healthcare Research Institute, Hennepin Healthcare, Minneapolis, Minnesota, USA.
Mark R NelsonMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Nigel P StocksDiscipline of General Practice, University of Adelaide, Adelaide, South Australia, Australia.
Rory WolfeDepartment of Epidemiology & Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Christopher M ReidDepartment of Epidemiology & Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Danny LiewDepartment of Epidemiology & Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Robyn L WoodsDepartment of Epidemiology & Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
ASPREE Investigator Group
Monash University · AUCurtin University · AUThe University of Adelaide · AUUniversity of Iowa · USUniversity of Minnesota · USUniversity of Tasmania · AU

Funding

ASPirin in Reducing Events in the ElderlyU01AG029824 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MCNEIL, JOHN JAMES, MURRAY, ANNE M · 2009 to 2018
$64.6M
Main Administrative CoreU19AG062682 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI CHAN, ANDREW T, MCNEIL, JOHN JAMES · 2019 to 2023
$42.9M
Research Education CoreP30AG024824 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Neil Alexander · 2004 to 2026
$29.2M
San Antonio OAIC - Research Education Component (REC)P30AG044271 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Adam Salmon · 2015 to 2026
$14.1M
NIA NIH HHS P30 AG024824NIA NIH HHS P30 AG044271NIA NIH HHS U01 AG029824NIA NIH HHS U01AG029824NIA NIH HHS U19 AG062682
6 · The paper itself

Abstract

backgroundEfforts to minimize medication risks among older adults include avoidance of potentially inappropriate medications. Contemporary analysis of medication use in community-dwelling older people compared with the general population is lacking.

participantsA total of 19,114 community-dwelling adults in Australia and the United States aged 70 years or older (65 years or older for U.S. minorities) without histories of major cardiovascular disease, cognitive impairment, or disability participated in a randomized, placebo-controlled trial of aspirin: ASPirin in Reducing Events in the Elderly study. Measurements Prescribed baseline medications obtained by self-report and medical record review were grouped by World Health Organization Anatomic and Therapeutic Chemical category. Potentially inappropriate medications were defined using a modified American Geriatrics Society Beers Criteria. Polypharmacy was defined as 5 or more medications, and hyperpolypharmacy defined as 10 or more medications. Cross-sectional descriptive statistics and adjusted odds ratios were computed.

resultsThe median number of prescription medications per participant was three, regardless of age. Women had a higher medication prevalence. Cardiovascular drugs (primarily antihypertensives) were the most commonly reported (64%). Overall, 39% of the cohort reported taking at least one potentially inappropriate medication, with proton-pump inhibitors being the most commonly reported (21.2% of cohort). Of the cohort, 27% had polypharmacy, and 2% hyperpolypharmacy. Age 75 years or older, less than 12 years of education, hypertension, diabetes mellitus, chronic kidney disease, frailty, gastrointestinal complaint, and depressive symptoms were associated with an increased likelihood of potentially inappropriate medications and polypharmacy. For almost all medication classes, prevalence was equivalent or lower than the general older population.

conclusionOverall medication burden and polypharmacy are low in older adults free of major cardiovascular disease, disability, and cognitive impairment. The prevalence of potentially inappropriate medications is higher than previously reported and similar to more vulnerable populations as a result of the introduction of proton-pump inhibitors to the American Geriatrics Society Beers Criteria. Longitudinal follow-up is required to further understand the balance of benefits and risks for potentially inappropriate medications and polypharmacy in community-dwelling older people.

Indexed as

AspirinCardiovascular DiseasesPlatelet Aggregation InhibitorsPotentially Inappropriate Medication ListAgedAged, 80 and overAustraliaCross-Sectional StudiesDouble-Blind MethodFemaleHealth Services for the AgedHumansMalePolypharmacyRandomized Controlled Trials as TopicUnited StatesAspirinPlatelet Aggregation Inhibitorshealthy agingpharmacoepidemiologypolypharmacypotentially inappropriate medications

Identifiers

PMID33078479
PMCPMC7957955
OpenAlexW3093281218

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.